Endpoints News 3 juin 2026 Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Endpoints News 2 juin 2026 FDA details flexibilities for new cell and gene therapies to leverage past data
Endpoints News 2 juin 2026 What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
Endpoints News 2 juin 2026 Male contraception startup closes $92.5M Series B; Novartis bets on actinium
Endpoints News 2 juin 2026 Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
Endpoints News 2 juin 2026 #ASCO26: Celcuity plans another FDA filing after positive breast cancer readout
Endpoints News 2 juin 2026 Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
Endpoints News 2 juin 2026 Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Endpoints News 2 juin 2026 Praxis sinks on late-stage study fail for seizure pill, halts second trial